LTRN (Lantern Pharma) Cash-to-Debt : 98.41 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Lantern Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lantern Pharma's cash to debt ratio for the quarter that ended in Dec. 2024 was 98.41.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Lantern Pharma could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Lantern Pharma's Cash-to-Debt or its related term are showing as below:

LTRN' s Cash-to-Debt Range Over the Past 10 Years
Min: 11.96 Med: 197.72 Max: No Debt
Current: 96.41

During the past 7 years, Lantern Pharma's highest Cash to Debt Ratio was No Debt. The lowest was 11.96. And the median was 197.72.

LTRN's Cash-to-Debt is ranked better than
77.72% of 1481 companies
in the Biotechnology industry
Industry Median: 7.56 vs LTRN: 96.41

Lantern Pharma Cash-to-Debt Historical Data

The historical data trend for Lantern Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lantern Pharma Cash-to-Debt Chart

Lantern Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

176.41

345.00

1,041.43

176.51

98.41

Lantern Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															176.51	197.72	151.88	96.41	98.41

Competitive Comparison of Lantern Pharma's Cash-to-Debt

For the Biotechnology subindustry, Lantern Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lantern Pharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lantern Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lantern Pharma's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Lantern Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lantern Pharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	24.013	/	(0.191	+	0.053)
	=	98.41

Lantern Pharma's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	24.013	/	(0.191	+	0.053)
	=	98.41

Lantern Pharma (NAS:LTRN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Lantern Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Lantern Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Lantern Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lantern Pharma Inc (NAS:LTRN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201

Website

https://www.lanternpharma.com

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Executives

Leslie W. Kreis	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund I, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund I Qp, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Cavu Management, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Advisors Gp, Llc	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Cavu Advisors, Llc	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bp Directors, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Fletcher Aaron G.l.	10 percent owner	40 GUEST STREET, BOSTON MA 02135
Maria-luisa Maccecchini	director	1223 FOXGLOVE LANE, WEST CHESTER PA 19380